Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
By
Danish Memon,
Hira Rizvi,
George Fromm,
Jayon Lihm,
Adam J Schoenfeld,
Jennifer L Sauter,
Jia Luo,
Andrew Chow,
Umesh K Bhanot,
Caroline McCarthy,
Darwin Ye,
Chad M Vanderbilt,
Cailian Liu,
Mohsen Abu-Akeel,
Andrew J Plodkowski,
Nicholas McGranahan,
Marta Luksza,
Benjamin D. Greenbaum,
Taha Merghoub,
Andy J. Minn,
Pedro Beltrao,
Taylor H Schreiber,
Martin L Miller,
Matthew D. Hellmann
Posted 22 Jul 2021
bioRxiv DOI: 10.1101/2021.07.21.452854
Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinically characterize acquired resistance, finding it to be common (occurring in more than 60% of initial responders), with persistent but diminishing risk over time, and with distinct metastatic and survival patterns compared to primary resistance. To examine the molecular phenotype and potential mechanisms of acquired resistance, we performed whole transcriptome and exome tumor profiling in a subset of NSCLC patients (n=29) with acquired resistance. Systematic immunogenomic analysis revealed that tumors with acquired resistance generally had enriched signals of inflammation (including IFN{gamma} signaling and inferred CD8+ T cells) and could be separated into IFN{gamma} upregulated and stable subsets. IFN{gamma} upregulated tumors had putative routes of resistance with signatures of dysfunctional interferon signaling and mutations in antigen presentation genes. Transcriptomic profiling of cancer cells from a murine model of acquired resistance to PD-(L)1 blockade also showed evidence of dysfunctional interferon signaling and acquired insensitivity to in vitro interferon gamma treatment. In summary, we characterized clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC and found evidence of ongoing but dysfunctional IFN response. The persistently inflamed, rather than excluded or deserted, tumor microenvironment of acquired resistance informs therapeutic strategies to effectively reprogram and reverse acquired resistance.
Download data
- Downloaded 701 times
- Download rankings, all-time:
- Site-wide: 57,068
- In cancer biology: 2,077
- Year to date:
- Site-wide: 15,710
- Since beginning of last month:
- Site-wide: 11,873
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!